INDUSTRY ENGAGEMENT - PROTEOMICS
Proteomics is increasingly being employed by Australian industry for new product development and testing applications.

Advanced protein analysis technologies can reveal the structure and function of proteins and their complex interactions. Proteomic investigations have diverse commercial applications including drug development, crop resilience, food safety and quality control processes.

The Australian Proteome Analysis Facility (APAF) is a high throughput proteomics laboratory offering world class research services in protein analysis. As a key partner in the Bioplatforms Australia infrastructure network, APAF’s scientific infrastructure and expertise is broadly accessed by Australian and international companies of all sizes from diverse industries.

INNOVATION PIPELINE
APAF’s commercial collaborations can occur anywhere within the development spectrum from innovation to end-user and most significantly support pharmaceutical, biotech, food and agricultural companies.

Proteomics advances have created highly sensitive methods to identify and measure protein changes in cells and tissue making it an important discovery tool for identifying biological markers. These techniques also allow the development of novel biomarker assays to guide product R&D and provide a quantitative method for validation and quality control processes.
CASE STUDIES

ROCHE
Pharmaceutical company, Roche has contracted APAF’s mass spectrometry expertise to develop and apply novel protein biomarker assays for a Phase IV clinical trial of bevacizumab in metastatic colorectal cancer.

RESMED
Australian medical device company, ResMed has worked with APAF to identify protein biomarkers associated with sleep apnoea.

THE A2 MILK COMPANY
APAF and a2 Milk have collaborated on numerous projects to characterise new and existing products as well as to develop new analytical testing procedures.

PFIZER
APAF has been collaborating with Pfizer’s global research teams for over eight years. Projects early in the innovation pipeline have sought new biological knowledge in model systems. Further along the pipeline, they have supported preclinical studies seeking pharmacodynamic biomarkers of drug action.

TEVA PHARMACEUTICAL AUSTRALIA
Teva Pharmaceuticals have established a service arrangement that employs APAF’s expertise in peptide and glycan analysis to characterise biologic entities. This partnership lead to the development of new characterisation services which are utilised by other biotech companies to support commercialisation and registration of biologic entities.

NCRIS
National Research Infrastructure for Australia
An Australian Government Initiative

Bioplatforms Australia Ltd
Andrew Gilbert
T | 02 9850 6200
M | 0410 538 648
www.bioplatforms.com

Bioplatforms Australia is a non-profit organisation that supports Australian life science research with crucial investments in state-of-the-art ‘omics technologies and cutting edge expertise. Investment funding has been provided through the Commonwealth Government National Collaborative Research Infrastructure Strategy, 2009 EIF Super Science Initiative and the Collaborative Research Scheme. Co-investments have been made by State Governments, research institutes and commercial entities.